NCT07272057

SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

The Impact of SGLT2i on the Outcome of Advanced Lung Cancer in Patients With Diabetes

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Shanghai Chest Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are: * Does adding an SGLT2 inhibitor to standard cancer treatment improve survival? * Does it cause more or fewer cardiovascular toxicity? * What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works. Participants will: * Be adults diagnosed with advanced lung cancer and type 2 diabetes. * Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment. * Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	SGLT-2 inhibitor	SGLT2 inhibitors used for patients with lung cancer and diabetes
OTHER	Sham (No Treatment)	SGLT2 inhibitors are not used for patients with lung cancer and diabetes

Timeline

• Start date: 2025-12-07
• Primary completion: 2026-10-07
• Completion: 2026-11-07
• First posted: 2025-12-09
• Last updated: 2025-12-09